Evaluating the Relationship Between Environmental Risk Factors in Housing Types and Chronic Respiratory Diseases in Ho Chi Minh City
3. August 2017 aktualisiert von: Olivier Michel, Brugmann University Hospital
The research question is "Are the different types of house in Ho Chi Minh city equally contributing to chronic respiratory diseases?".
According to this question, a cross-sectional and explorative study was set up to explore the differences in the environmental characteristics and prevalence of chronic respiratory diseases among common housing types in Ho Chi Minh city. Preliminary work was performed in 100 houses (20 houses per type, included tube houses, rental houses, rural houses, slum and apartment) from November 2013 to June 2015. It included measures by environmental devices, questionnaires and indoor activities diaries.
This study will aim to collect information about the prevalence of chronic respiratory diseases (CRDs) inside those house types to understand more about role of house types in developing CRDs.
The objective is:
- to evaluate the relationships between the type of house and lung function of inhabitants in each housing type.
- to evaluate the effects of environmental risk factors in each house type on prevalence of CRDs
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
1500
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Ho Chi Minh City, Vietnam, 7000
- Pham Ngoc Thach University of Medicine
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
10 Jahre bis 65 Jahre (Kind, Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Everybody
Exclusion Criteria:
- Not able to answer the questionnaire or give informed consent
- Have a contra-indication for lung function test (acute myocardial infarction less that 1 month ago, pain related to spirometry, dementia/confused)
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Screening
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Tube houses
Tube Houses.
Group of 75-100 houses, with 4 inhabitants per house.
Expected number of participants: 300-400.
Predicted number of non-smoker chronic respiratory disease of 18-24.
|
Basic lung function test performed with a micro-spirometer, without broncho dilatator
|
|
Experimental: Apartment
Apartments.
Group of 75-100 apartments, with 4 inhabitants per apartment.
Expected number of participants: 300-400.
Predicted number of non-smoker chronic respiratory disease of 18-24.
|
Basic lung function test performed with a micro-spirometer, without broncho dilatator
|
|
Experimental: Rental Houses
Rental Houses.
Group of 150-200 rental houses, with 2 inhabitants per rental house.
Expected number of participants: 300-400.
Predicted number of non-smoker chronic respiratory disease of 18-24.
|
Basic lung function test performed with a micro-spirometer, without broncho dilatator
|
|
Experimental: Rural houses
Rural Houses.
Group of 40-60 rural houses, with 5 inhabitant per rural house.
Expected number of participants: 200-300.
Predicted number of non-smoker chronic respiratory disease of 12-18.
|
Basic lung function test performed with a micro-spirometer, without broncho dilatator
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
FEV1/FVC
Zeitfenster: 5 minutes
|
Basic lung function test, without broncho dilatation (micro-spirometer).
All lung function related outcomes are performed during the same test.
FEV1: forced expiratory volume in one second.
FVC: Forced vital capacity.
|
5 minutes
|
|
FVC
Zeitfenster: 5 minutes
|
Basic lung function test, without broncho dilatation (micro-spirometer).
All lung function related outcomes are performed during the same test.FVC: Forced vital capacity.
|
5 minutes
|
|
VC
Zeitfenster: 5 minutes
|
Basic lung function test, without broncho dilatation (micro-spirometer).
All lung function related outcomes performed during the same test.
VC: Vital capacity
|
5 minutes
|
|
FEF 25-75%
Zeitfenster: 5 minutes
|
Basic lung function test, without broncho dilatation (micro-spirometer).All lung function related outcomes are performed during the same test.
FEF: Forced expiratory flow
|
5 minutes
|
|
Socio-demographic status
Zeitfenster: around 10 minutes
|
Socio-demographic data, assessed by a home made questionnaire
|
around 10 minutes
|
|
Health status
Zeitfenster: around 10 minutes
|
Health status (symptomatology) data, assessed by a home made questionnaire
|
around 10 minutes
|
|
Indoor air exposure time
Zeitfenster: around 10 minutes
|
Indoor air exposure (time spent indoor within housing types, with associated air characteristics) data, assessed by a home made questionnaire
|
around 10 minutes
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Allgemeine Veröffentlichungen
- Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948-68. doi: 10.1183/09031936.05.00035205. No abstract available.
- Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis. 1991 Nov;144(5):1202-18. doi: 10.1164/ajrccm/144.5.1202. No abstract available.
- Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993 Mar;16:5-40. No abstract available.
- Flohr C, Tuyen LN, Quinnell RJ, Lewis S, Minh TT, Campbell J, Simmons C, Telford G, Brown A, Hien TT, Farrar J, Williams H, Pritchard DI, Britton J. Reduced helminth burden increases allergen skin sensitization but not clinical allergy: a randomized, double-blind, placebo-controlled trial in Vietnam. Clin Exp Allergy. 2010 Jan;40(1):131-42. doi: 10.1111/j.1365-2222.2009.03346.x. Epub 2009 Sep 15.
- Dherani M, Pope D, Mascarenhas M, Smith KR, Weber M, Bruce N. Indoor air pollution from unprocessed solid fuel use and pneumonia risk in children aged under five years: a systematic review and meta-analysis. Bull World Health Organ. 2008 May;86(5):390-398C. doi: 10.2471/blt.07.044529.
- Ezzati M, Kammen DM. The health impacts of exposure to indoor air pollution from solid fuels in developing countries: knowledge, gaps, and data needs. Environ Health Perspect. 2002 Nov;110(11):1057-68. doi: 10.1289/ehp.021101057.
- Bruce N, Perez-Padilla R, Albalak R. Indoor air pollution in developing countries: a major environmental and public health challenge. Bull World Health Organ. 2000;78(9):1078-92.
- Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official Statement of The European Respiratory Society. Eur Respir J. 1995 Mar;8(3):492-506. doi: 10.1183/09031936.95.08030492. No abstract available.
- American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique--1995 update. Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2185-98. doi: 10.1164/ajrccm.152.6.8520796. No abstract available.
- Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993 Mar;16:41-52. No abstract available.
- Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol. 1993 Feb;15(2):75-88. doi: 10.1002/ppul.1950150204.
- Quanjer PH, Stocks J, Polgar G, Wise M, Karlberg J, Borsboom G. Compilation of reference values for lung function measurements in children. Eur Respir J Suppl. 1989 Mar;4:184S-261S. No abstract available.
- COPD-more than just tobacco smoke. Lancet. 2009 Aug 29;374(9691):663. doi: 10.1016/S0140-6736(09)61535-X. No abstract available.
- Bousquet J, Kiley J, Bateman ED, Viegi G, Cruz AA, Khaltaev N, Ait Khaled N, Baena-Cagnani CE, Barreto ML, Billo N, Canonica GW, Carlsen KH, Chavannes N, Chuchalin A, Drazen J, Fabbri LM, Gerbase MW, Humbert M, Joos G, Masjedi MR, Makino S, Rabe K, To T, Zhi L. Prioritised research agenda for prevention and control of chronic respiratory diseases. Eur Respir J. 2010 Nov;36(5):995-1001. doi: 10.1183/09031936.00012610. Epub 2010 Mar 11.
- Samet JM, Spengler JD. Indoor environments and health: moving into the 21st century. Am J Public Health. 2003 Sep;93(9):1489-93. doi: 10.2105/ajph.93.9.1489.
- Bardana EJ Jr. Indoor pollution and its impact on respiratory health. Ann Allergy Asthma Immunol. 2001 Dec;87(6 Suppl 3):33-40. doi: 10.1016/s1081-1206(10)62338-1.
- Smith KR. Indoor air pollution in developing countries: recommendations for research. Indoor Air. 2002 Sep;12(3):198-207. doi: 10.1034/j.1600-0668.2002.01137.x.
- Smith KR, Mehta S. The burden of disease from indoor air pollution in developing countries: comparison of estimates. Int J Hyg Environ Health. 2003 Aug;206(4-5):279-89. doi: 10.1078/1438-4639-00224.
- Smith KR, Samet JM, Romieu I, Bruce N. Indoor air pollution in developing countries and acute lower respiratory infections in children. Thorax. 2000 Jun;55(6):518-32. doi: 10.1136/thorax.55.6.518.
- Rojas-Bracho L, Suh HH, Koutrakis P. Relationships among personal, indoor, and outdoor fine and coarse particle concentrations for individuals with COPD. J Expo Anal Environ Epidemiol. 2000 May-Jun;10(3):294-306. doi: 10.1038/sj.jea.7500092.
- Sarnat JA, Koutrakis P, Suh HH. Assessing the relationship between personal particulate and gaseous exposures of senior citizens living in Baltimore, MD. J Air Waste Manag Assoc. 2000 Jul;50(7):1184-98. doi: 10.1080/10473289.2000.10464165.
- Jaakkola MS. Environmental tobacco smoke and health in the elderly. Eur Respir J. 2002 Jan;19(1):172-81. doi: 10.1183/09031936.02.00270702.
- Smith KR. National burden of disease in India from indoor air pollution. Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13286-93. doi: 10.1073/pnas.97.24.13286.
- Briggs D. Environmental pollution and the global burden of disease. Br Med Bull. 2003;68:1-24. doi: 10.1093/bmb/ldg019.
- Raw GJ, Coward SK, Brown VM, Crump DR. Exposure to air pollutants in English homes. J Expo Anal Environ Epidemiol. 2004;14 Suppl 1:S85-94. doi: 10.1038/sj.jea.7500363.
- Viegi G, Simoni M, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L, Annesi-Maesano I. Indoor air pollution and airway disease. Int J Tuberc Lung Dis. 2004 Dec;8(12):1401-15.
- Levesqu B, Allaire S, Gauvin D, Koutrakis P, Gingras S, Rhainds M, Prud'Homme H, Duchesne JF. Wood-burning appliances and indoor air quality. Sci Total Environ. 2001 Dec 17;281(1-3):47-62. doi: 10.1016/s0048-9697(01)00834-8.
- Naeher LP, Smith KR, Leaderer BP, Neufeld L, Mage DT. Carbon monoxide as a tracer for assessing exposures to particulate matter in wood and gas cookstove households of highland Guatemala. Environ Sci Technol. 2001 Feb 1;35(3):575-81. doi: 10.1021/es991225g.
- Rollin HB, Mathee A, Bruce N, Levin J, von Schirnding YE. Comparison of indoor air quality in electrified and un-electrified dwellings in rural South African villages. Indoor Air. 2004 Jun;14(3):208-16. doi: 10.1111/j.1600-0668.2004.00238.x.
- Schwela D. Cooking smoke: a silent killer. People Planet. 1997;6(3):24-5.
- Wolkoff P, Schneider T, Kildeso J, Degerth R, Jaroszewski M, Schunk H. Risk in cleaning: chemical and physical exposure. Sci Total Environ. 1998 Apr 23;215(1-2):135-56. doi: 10.1016/s0048-9697(98)00110-7.
- Delfino RJ. Epidemiologic evidence for asthma and exposure to air toxics: linkages between occupational, indoor, and community air pollution research. Environ Health Perspect. 2002 Aug;110 Suppl 4(Suppl 4):573-89. doi: 10.1289/ehp.02110s4573.
- Payne-Sturges DC, Burke TA, Breysse P, Diener-West M, Buckley TJ. Personal exposure meets risk assessment: a comparison of measured and modeled exposures and risks in an urban community. Environ Health Perspect. 2004 Apr;112(5):589-98. doi: 10.1289/ehp.6496.
- Regional COPD Working Group. COPD prevalence in 12 Asia-Pacific countries and regions: projections based on the COPD prevalence estimation model. Respirology. 2003 Jun;8(2):192-8. doi: 10.1046/j.1440-1843.2003.00460.x.
- Tan WC, Ng TP. COPD in Asia: where East meets West. Chest. 2008 Feb;133(2):517-27. doi: 10.1378/chest.07-1131.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. September 2016
Primärer Abschluss (Tatsächlich)
1. Juli 2017
Studienabschluss (Tatsächlich)
1. Juli 2017
Studienanmeldedaten
Zuerst eingereicht
8. September 2016
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
8. September 2016
Zuerst gepostet (Schätzen)
13. September 2016
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
4. August 2017
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
3. August 2017
Zuletzt verifiziert
1. August 2017
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CHUB-CRD-Housing
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Chronische Atemwegserkrankungen
-
Nicola IrwinAbgeschlossenRespiratory-Syncytial-Virus-Krankenhausaufenthalte | Respiratory-Syncytial-Virus-Prävention | Respiratory Syncytial Virus (RSV)-InfektionAustralien
-
Nicola IrwinThe University of New South Wales; Kirby InstituteAbgeschlossenRespiratory-Syncytial-Virus-Krankenhausaufenthalte | Infektion mit dem Respiratory Syncytial Virus (RSV). | Immunisierung gegen respiratorische SynzytialvirenAustralien
-
MAXVAX Biotechnology Limited Liability CompanyHenan Center for Disease Control and PreventionNoch keine Rekrutierung
-
PfizerRekrutierungRespiratory-Syncytial-Virus (RSV)Japan
-
MAXVAX Biotechnology Limited Liability CompanySichuan Center for Disease Control and Prevention; Hunan Provincial Center for... und andere MitarbeiterRekrutierungRespiratory-Syncytial-Virus (RSV)China
-
Emory UniversityOpen PhilanthropyAktiv, nicht rekrutierendRespiratory-Syncytial-Virus (RSV)Vereinigte Staaten
-
PfizerAktiv, nicht rekrutierendRespiratory-Syncytial-Virus (RSV)Vereinigte Staaten
-
MAXVAX Biotechnology Limited Liability CompanyNoch keine RekrutierungRespiratory-Syncytial-Virus (RSV)Australien
-
Guangzhou Patronus Biotech Co., Ltd.Aktiv, nicht rekrutierendRespiratory-Syncytial-Virus-InfektionspräventionChina
-
Simcere Pharmaceutical Co., LtdRekrutierungRespiratory-Syncytial-Virus-InfektionChina